

Olaparib OlympiAD

## PRELIMINARY SCORE

### CURATIVE




### NON-CURATIVE




## ADJUSTMENTS

### Quality of life



Delayed deterioration of QoL

### Serious and disabling adverse effects



Less serious and disabling adverse events observed

### Other adjustments



Olaparib OlympiAD

## FINAL SCORE

### CURATIVE



Overall Survival / Disease-Free Survival / Pathological Complete Response

### NON-CURATIVE



Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

### INFORMATION

Therapeutic Indication: Treatment of patients with germline BRCA1/2 mutations, who have HER2-negative locally advanced or MBC who have been previously treated with an anthracycline and a taxane in the (neo)adjuvant or metastatic setting unless unsuitable for these treatments

Experimental Arm: Olaparib

Control Arm: Standard chemotherapy



